Microbot Medical Inc. Schedules its Periodical Townhall Meeting for Monday, June 4th at 9:00 a.m., Eastern Time
Recent Significant Milestones
- In-vitro study, which was performed at
Wayne State University, supports the SCS’s potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus.
- In-vivo study, which was performed at
Washington University School of Medicinein St. Louis, supports the safety profile of the Company’s SCS as a CSF catheter.
- Closed the previously announced acquisition of a novel patent-protected technology from
CardioSert Ltd., providing the Company with CardioSert’s innovative technology, including R&D information, technical know-how and intellectual property. The State Intellectual Property Office of Chinaissued a Notification of Granting a Patent Right for Chinese Patent Application No. 201410432156.7, which covers the Company’s ViRob™ technology platform.
- Relocated its global Research & Development facility to the Caesarea Business and
Industrial Park, located in Caesarea, Israel. The new 6,000 square feet facility houses the Company’s entire Israeloperations, including engineering, research, manufacturing, clinical and commercial teams and includes a laboratory with a clean area to allow production, as well as evaluating and supporting the development of new concepts around micro-robotics medical products.
Townhall Conference Call Details
For both “listen-only” participants and those participants who wish to ask questions, the dial-in number is 888-312-3052 (U.S./
A replay of the ‘Townhall Meeting will be available for seven business days beginning about two hours after the conclusion of the live call, by dialing 888-203-1112 (U.S./
Microbot, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on
The ViRobTM technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRobTM please visit http://www.microbotmedical.com/technology/virob/.
TipCATTM is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCATTM, visit http://www.microbotmedical.com/technology/tipcat/.
CardioSertTM technology is a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal surgery. The CardioSertTM technology features unique steering and stiffness control capabilities, and it was originally developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as peripheral intervention, neurosurgery and urology. CardioSertTM was part of a technological incubator supported by the Israel Innovation Authorities (formerly known as the
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for